We provide you with 20 years of free, institutional-grade data for ANNX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANNX. Explore the full financial landscape of ANNX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
Name | Action | Shares | Avg Price | Amount | Reported Date |
---|---|---|---|---|---|
Carson William H. | Open Market Purchase | 3,200 | $4.83 | 2024-06-05 | |
Carson William H. | Open Market Purchase | 3,200 | $4.68 | 2024-05-03 | |
Carson William H. | Open Market Purchase | 3,200 | $6.07 | 2024-04-10 | |
Lew Jennifer | Sale | -2,593 | $5.53 | $14,339 | 2024-02-21 |
Lew Jennifer | Grant, award...etc | 39,000 | 2024-02-21 | ||
Dananberg Jamie | Grant, award...etc | 39,000 | 2024-02-21 | ||
ARTIS DEAN RICHARD | Grant, award...etc | 39,000 | 2024-02-21 | ||
Yednock Ted | Sale | -2,604 | $5.51 | $14,348 | 2024-02-21 |
Yednock Ted | Grant, award...etc | 39,000 | 2024-02-21 | ||
Overdorf Michael | Sale | -1,951 | $5.48 | $10,691 | 2024-02-21 |
Overdorf Michael | Grant, award...etc | 39,000 | 2024-02-21 | ||
Yednock Ted | Sale | -1,810 | $5.54 | $10,027 | 2024-02-14 |
Love Douglas | Sale | -5,782 | $5.54 | $32,032 | 2024-02-14 |
Overdorf Michael | Sale | -1,349 | $5.53 | $7,460 | 2024-02-14 |
Lew Jennifer | Sale | -1,809 | $5.54 | $10,022 | 2024-02-14 |
Lew Jennifer | Sale | -1,057 | $3.84 | $4,055 | 2024-01-23 |
Overdorf Michael | Sale | -978 | $3.84 | $3,752 | 2024-01-23 |
Yednock Ted | Derivatives Exercise | 21,000 | 2024-01-23 | ||
Yednock Ted | Sale | -22,057 | $3.84 | $84,613 | 2024-01-23 |
Yednock Ted | Sale | -21,000 | $4.52 | $94,966 | 2023-12-29 |
Yednock Ted | Derivatives Exercise | 21,000 | 2023-12-29 | ||
Satter Muneer A | Open Market Purchase | 350,000 | $2.88 | 2023-12-28 | |
Bain Capital Life Sciences Investors, LLC | Open Market Purchase | 300,000 | $2.13 | 2023-05-30 | |
Yednock Ted | Initial | 2023-03-27 | |||
Overdorf Michael | Grant, award...etc | 18,975 | 2023-02-21 | ||
Lew Jennifer | Grant, award...etc | 18,975 | 2023-02-21 | ||
Love Douglas | Sale | -6,571 | $5.87 | $38,564 | 2023-02-17 |
Overdorf Michael | Sale | -1,645 | $6.3 | $10,369 | 2023-02-15 |
Lew Jennifer | Sale | -1,908 | $6.31 | $12,036 | 2023-02-15 |
Satter Muneer A | Open Market Purchase | 2,647,058 | $6.8 | 2023-02-14 | |
ARTIS DEAN RICHARD | Initial | 2023-01-12 | |||
Mattheakis Larry | Grant, award...etc | 9,376 | 2022-07-13 | ||
Lew Jennifer | Grant, award...etc | 9,375 | 2022-07-13 | ||
Overdorf Michael | Grant, award...etc | 9,375 | 2022-07-13 | ||
Satter Muneer A | Open Market Purchase | 2,453,988 | $3.84 | 2022-07-11 | |
Love Douglas | Open Market Purchase | 60,000 | $2.45 | 2022-04-18 | |
Keswani Sanjay | Grant, award...etc | 12,500 | 2022-02-15 | ||
Mattheakis Larry | Grant, award...etc | 12,500 | 2022-02-15 | ||
Lew Jennifer | Grant, award...etc | 12,500 | 2022-02-15 | ||
Love Douglas | Grant, award...etc | 40,000 | 2022-02-15 | ||
Overdorf Michael | Grant, award...etc | 12,500 | 2022-02-15 |
The information provided in this report about ANNX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Annexon, Inc(NASDAQ:ANNX)


Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders....
Website: http://www.annexonbio.com
Founded: 2011
Full Time Employees: 38
CEO: Douglas Love
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends